Please ensure Javascript is enabled for purposes of website accessibility

Teladoc's Earnings Had 1 Important Metric for Both Bulls and Bears

By Jason Hawthorne – Aug 8, 2021 at 6:50AM

Key Points

  • One number might mean things aren’t going back to the way they were.
  • Another one shows the company is bogged down by acquisition-related expenses.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Which story do you believe?

Stocks are driven by stories. Although long-term performance is determined by how much a company earns, its price at any given time is a reflection of the story market participants choose to believe. That's why markets have buyers and sellers. They believe different stories about the company's future.

The story for Teladoc Health (TDOC -3.40%) has gotten more complicated in the past two years. What was once a virtual health provider with crisp growth has morphed into the possible "future of healthcare" and one of the largest holdings of Cathie Wood's ARK Innovation ETF (NYSEMKT:ARKK), ARK Next Generation Internet ETF (NYSEMKT:ARKW), and ARK Genomics Revolution ETF (NYSEMKT:ARKG). After an enormous acquisition and mass vaccinations, others see a difficult path to profitability for the stock. The company's second quarter results aren't likely to change any opinions.

A doctor doing a virtual visit while sitting at a desk.

Image source: Getty Images.

Utilization continues to rise

One of the most important questions coming out of the pandemic is whether consumer behaviors have been permanently altered. Most people expect food delivery, e-commerce, and remote work to slow compared to the pace of growth in 2020. It's only natural that some people would flock back to restaurants, malls, and offices when they are safer. 

That seemed especially true of doctors' offices. Virtual visits became the norm last year but patients want to see their doctors in person -- or do they? Teladoc is seeing utilization -- the percent of its members who are taking advantage of virtual visits -- continuing to climb.

Period Utilization
Q2 2021 21.5%
Q1 2021 19.6%
Q4 2020 17.7%
Q3 2020 16.5%
Q2 2020 16%
Q1 2020 13.4%

Data source: Teladoc Health

For those expecting things to go back to the way they were, there is no evidence of that yet. Despite the drop off in visits associated with infectious disease, specialty care and non-infectious disease are picking up the baton. In the second quarter, 80% of member visits were for non-infectious disease compared to 50% before COVID. It's a great sign that the company's platform is becoming embedded in its members' healthcare decisions.

The merger with Livongo is a drag

Growth and customer engagement are only beneficial when the economics of the business work. For Teladoc, that means adding more members and services should lead to more revenue than costs. It's on track. Gross margin climbed from 60.6% through the first six months of 2020 to 67.4% over that span this year. Similarly, its adjusted earnings before interest taxes, depreciation, and amortization have steadily climbed with growth (EBITDA).

Period Revenue Revenue Growth Adj. EBITDA Margin EBITDA Margin
FY21 YTD $957 million 127% 12.9% (6.6%)
2020 $1.09 billion 98% 11.6% (40%)
2019 $553 million 32% 5.7% (7.5%)
2018 $418 million 79% 3.2% (8.4%)

Data source: Teladoc Health.

Those are adjusted numbers. The unadjusted numbers tell a different story. From that perspective, the company lost $333.5 million in the first half of 2021. That is a lot more than the $55.3 million it lost during the same six months last year. Much of the difference is related to its acquisition of Livongo, a chronic disease management company. 

Given its grand ambitions for "whole person" care, the $18.5 billion purchase price can be justified. But the costs continue to overwhelm any near-term financial benefit. Since the deal closed at the end of October, Teladoc has reported $780 million in Livongo-related expenses for stock-based compensation and associated taxes, amortization of intangibles, and extinguishing debt. Shareholders have to hope that's coming to an end soon. Those costs don't count the fact that there are now 156 million shares outstanding, a 104% increase from this time last year. 

What makes a market

Eventually, acquisition costs will subside and the benefit of having Livongo in the portfolio should show up on the bottom line. For now, shareholders will have to deal with messy financial statements and management's adjustments pointing to eventual profits.

For others, the expenses show a company that simply bit off more than it could chew, caught in a cycle of diluting shareholders to keep the growth story alive. The same numbers but a different story. The battle between the bulls and bears on Teladoc is likely to rage until well into 2022.

Jason Hawthorne owns shares of Teladoc Health. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health Stock Quote
Teladoc Health
$27.60 (-3.40%) $0.97
ARK Innovation ETF Stock Quote
ARK Innovation ETF
$36.00 (-0.88%) $0.32
ARK ETF Trust - ARK Next Generation Internet ETF Stock Quote
ARK ETF Trust - ARK Next Generation Internet ETF
$43.74 (-0.93%) $0.41
ARK ETF Trust - ARK Genomic Revolution ETF Stock Quote
ARK ETF Trust - ARK Genomic Revolution ETF
$31.70 (-0.56%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.